Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares	Mar. 31, 2023 USD ($) item $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Aug. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Deferred revenue, Long-term	$ 18,828		$ 19,128
Allowances on accounts receivable		$ 1,300
Other assets	26,417		15,403
Deferred revenue	36,533	38,090	35,740	$ 30,778
Deferred revenue, current portion	17,705		16,612
Total revenues	367,741	241,756
Deferred revenue, long-term portion	18,828		19,128
Revenue recognized during the period that was included in deferred revenues at the beginning of the period	7,048	3,988
Disruption at Change Healthcare
Allowances on accounts receivable	$ 54,300
Product
Approximate percentage of revenue collected within 9 months	90.00%
Billing collection period (in months)	9 months
Extended billing collection period (in months)	6 months
Cost of revenues	$ 158,833	147,754
Increased (decreased) revenues	2,100	5,700
(Increased) decreased net loss	$ 2,100	$ 5,700
(Increased) decreased net loss per share | $ / shares	$ 0.02	$ 0.05
Total revenues	$ 364,672	$ 237,797
Tests delivered in prior periods that were fully collected
Increased (decreased) revenues	33,700	(9,200)
(Increased) decreased net loss	$ 33,700	$ (9,200)
(Increased) decreased net loss per share | $ / shares	$ 0.28	$ (0.08)
Tests delivered in prior periods that were fully collected | Disruption at Change Healthcare
Allowances on accounts receivable	$ 4,000
Amounts not refunded to insurance carriers
Increased (decreased) revenues	2,300
(Increased) decreased net loss	$ 2,300
(Increased) decreased net loss per share | $ / shares	$ 0.02
Licensing and other
Cost of revenues	$ 307	$ 370
Total revenues	3,069	$ 3,959
Genetic testing services
Deferred revenue, current portion	14,900
Revenue recognized during the period that was included in deferred revenues at the beginning of the period	6,600
BGI Genomics
Revenue recognized	$ 44,000
Agreement term	10 years
Revenue, remaining performance obligation	$ 6,000
Deferred revenue, Long-term	17,300
Transaction price	50,000
Deferred revenue	18,500
Deferred revenue, current portion	1,200
Prepaid royalties	20,000
Deferred revenue, long-term portion	17,300
BGI Genomics | License and related development services
Number of performance obligations | item		2
Revenue, remaining performance obligation		$ 24,000
BGI Genomics | Sequencing services
Other assets	4,800					$ 6,000
BGI Genomics | Sequencing products
Other assets						4,000
Prepaid expenses and other current assets	3,000
BGI Genomics | Sequencing products and services
Other assets	1,800					$ 10,000
Equipment and services received	20
BGI Genomics | Oncology assay interpretation services
Revenue recognized	300	700
Revenue, remaining performance obligation			$ 20,000
Deferred revenue		600
Foundation Medicine ("FMI")
Revenue recognized	$ 24,300
Agreement term	5 years
Automatic renewals, successive period thereafter	1 year
Revenue, remaining performance obligation	$ 7,700
Deferred revenue, Long-term	1,600
Transaction price					$ 32,000
Deferred revenue, current portion	1,600
Prepaid royalties	5,000
Deferred revenue, long-term portion	1,600
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized	100	200
Revenue, remaining performance obligation		5,000
Deferred revenue	$ 3,200
Foundation Medicine ("FMI") | Oncology products
Revenue recognized		200
Revenue, remaining performance obligation		$ 19,300